JP6543272B2 - 低減された毒性を有するアンホテリシンｂ誘導体 - Google Patents

低減された毒性を有するアンホテリシンｂ誘導体

Info

Publication number
JP6543272B2
JP6543272B2 JP2016567865A JP2016567865A JP6543272B2 JP 6543272 B2 JP6543272 B2 JP 6543272B2 JP 2016567865 A JP2016567865 A JP 2016567865A JP 2016567865 A JP2016567865 A JP 2016567865A JP 6543272 B2 JP6543272 B2 JP 6543272B2
Authority
JP
Japan
Prior art keywords
epiamb
amb
mmol
solution
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016567865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518982A5 (enExample
JP2017518982A (ja
Inventor
ディー バーク，マーティン
ディー バーク，マーティン
イー ウノ，ブライス
イー ウノ，ブライス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2017518982A publication Critical patent/JP2017518982A/ja
Publication of JP2017518982A5 publication Critical patent/JP2017518982A5/ja
Application granted granted Critical
Publication of JP6543272B2 publication Critical patent/JP6543272B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2016567865A 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンｂ誘導体 Active JP6543272B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461994450P 2014-05-16 2014-05-16
US61/994,450 2014-05-16
US201462045907P 2014-09-04 2014-09-04
US62/045,907 2014-09-04
PCT/US2015/030965 WO2015175875A1 (en) 2014-05-16 2015-05-15 Amphotericin b derivative with reduced toxicity

Publications (3)

Publication Number Publication Date
JP2017518982A JP2017518982A (ja) 2017-07-13
JP2017518982A5 JP2017518982A5 (enExample) 2018-06-28
JP6543272B2 true JP6543272B2 (ja) 2019-07-10

Family

ID=54480735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567865A Active JP6543272B2 (ja) 2014-05-16 2015-05-15 低減された毒性を有するアンホテリシンｂ誘導体

Country Status (7)

Country Link
US (1) US9738677B2 (enExample)
EP (1) EP3142672B1 (enExample)
JP (1) JP6543272B2 (enExample)
CA (1) CA2981288C (enExample)
DK (1) DK3142672T3 (enExample)
ES (1) ES2749927T3 (enExample)
WO (1) WO2015175875A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061437A1 (en) 2014-10-17 2016-04-21 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin b
EP3283171B1 (en) 2015-04-15 2021-05-26 Sfunga Therapeutics, Inc. Derivatives of amphotericin b
CN113056274A (zh) 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物
WO2021026450A1 (en) * 2019-08-08 2021-02-11 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity
WO2021030183A1 (en) * 2019-08-09 2021-02-18 The Board Of Trustees Of The University Of Illinois Combination treatment of systemic fungal infections
MX2023001649A (es) * 2020-08-10 2023-04-24 Univ Illinois Derivados de amida hibrida de anfotericina b.
EP4551584A2 (en) * 2022-07-08 2025-05-14 The Board Of Trustees Of The University Of Illinois Transfer of c2'-epimerized sugars to the amphotericin b aglycone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528704A (ja) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
CN101442989B (zh) * 2004-06-21 2013-04-03 诺瓦帝斯公司 包括两性霉素b的组合物
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2014059436A1 (en) * 2012-10-12 2014-04-17 The Board Of Trustees Of The University Of Illinois Electronic tuning of site selectivity
WO2016061437A1 (en) * 2014-10-17 2016-04-21 The Board Of Trustees Of The University Of Illinois Scalable synthesis of reduced toxicity derivative of amphotericin b

Also Published As

Publication number Publication date
EP3142672B1 (en) 2019-09-25
EP3142672A4 (en) 2017-11-15
US9738677B2 (en) 2017-08-22
CA2981288C (en) 2022-12-06
WO2015175875A1 (en) 2015-11-19
EP3142672A1 (en) 2017-03-22
DK3142672T3 (da) 2019-10-21
US20170088572A1 (en) 2017-03-30
JP2017518982A (ja) 2017-07-13
CA2981288A1 (en) 2015-11-19
ES2749927T3 (es) 2020-03-24

Similar Documents

Publication Publication Date Title
JP6543272B2 (ja) 低減された毒性を有するアンホテリシンｂ誘導体
EP3055030B1 (en) Amphotericin b derivatives with improved therapeutic index
AU2009308182B2 (en) Biodefenses using triazole-containing macrolides
WO2014165676A1 (en) Amphotericin b derivative with reduced toxicity
Vita et al. Targeting Helicobacter pylori for antibacterial drug discovery with novel therapeutics
WO2016014779A1 (en) Antifungal polyene macrolide derivatives with reduced mammalian toxicity
AU2011255633B2 (en) Methods of treating recurring bacterial infection
JP2017532329A (ja) アムホテリシンｂの毒性が低減された誘導体の規模変更可能な合成法
JP2009512691A (ja) クロストリジウムディフィシレ関連の下痢の治療方法
CN113336811B (zh) 环烯醚萜苷类化合物及其制备和应用
WO2016040779A1 (en) Urea derivatives of polyene macrolide antibiotics
WO2014049356A1 (en) Erythromycin ketolide derivatives bearing c-10 modifications
Masood-ur-Rahman et al. Synthesis and antimicrobial activity of triazolyl analogs of diosgenin
EP2669288A1 (en) New monosaccharide derivatives and biological applications thereof
Endo Synthesis-enabled understanding of the mechanism of action of amphotericin B and the development of increased therapeutic derivatives
WO1999052922A1 (en) ANTIMICROBIAL βGalNAc(1→4)βGal DERIVATIVES AND METHODS OF USE
Fan et al. Medical Potential of Insect Symbionts
Zhang Amphotericin B extracts ergosterol faster than fungi can make it
JP2023537921A (ja) アムホテリシンｂのハイブリッドアミド誘導体
NZ757647B2 (en) Amphotericin B derivatives with improved therapeutic index

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190515

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190614

R150 Certificate of patent or registration of utility model

Ref document number: 6543272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250